# Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

> **NCT07226713** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 32 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Pacritinib

## Key facts

- **NCT ID:** NCT07226713
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2031-03-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226713, "Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07226713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*